 CAMBRIDGE, Mass. MONTREAL--BUSINESS WIRE--Repare Therapeutics Inc. Repare or the Company Nasdaq: RPTX, a leading clinical-stage precision oncology company, today announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 12 TRESR Treatment Enabled by SNIPRx clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR Ataxia-Telangiectasia and Rad3-related protein kinase for the treatment of solid tumors with specific syn 